维生素K状态、补充与血管疾病:系统综述与荟萃分析
结果显示维生素K补充显著降低VC(-9.1%,95%CI -17.7至-0.5;p=0.04)和VKDP水平,但对VS改善不显著;VKDP水平与CVD或死亡联合终点相关(HR 0.45,95%CI 0.07至0.83;p=0.02)。结论受研究数量少和异质性大限制,需更大规模临床试验。
要点
- 维生素K补充可显著降低血管钙化,但对血管僵硬度改善不显著。
- 无活性VKDP水平与CVD或死亡联合终点相关(HR 0.45)。
- 证据受研究数量少和异质性大限制,需更大规模试验。
核心结论
- 与对照相比,维生素K补充显著降低血管钙化,但未显著改善血管僵硬度。
- 无活性VKDP水平与CVD或死亡联合终点相关。
- 结论受研究数量少和异质性大限制,需更大规模临床试验。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane和ISRCTN注册库。
- 采用随机效应荟萃分析。
主要发现
- 维生素K补充组血管钙化较对照组降低9.1%(95%CI -17.7至-0.5;p=0.04)。
- 维生素K补充组dp-ucMGP降低44.7%(95%CI -65.1至-24.3;p<0.0001)。
- 维生素K补充组ucOC降低12.0%(95%CI -16.7至-7.2;p<0.0001)。
- 血管僵硬度改善不显著。
- 纵向研究中位随访7.8年(IQR 4.9-11.3),VKDP水平与CVD或死亡联合终点相关(HR 0.45,95%CI 0.07至0.83;p=0.02)。
临床怎么用
- 维生素K补充可能用于改善血管钙化,但对血管僵硬度效果不显著。
- VKDP水平或可作为CVD或死亡风险的关联指标。
- 需更大规模临床试验验证维生素K补充对长期心血管健康的影响。
局限性
- 研究数量少。
- 研究间存在显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Vascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality. METHODS: Two authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed. RESULTS: Thirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (-9.1% (95% CI -17.7 to -0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; -44.7% (95% CI -65.1 to -24.3), p<0.0001) and uncarboxylated osteocalcin; -12.0% (95% CI -16.7 to -7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9-11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02). CONCLUSIONS: Supplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted. TRIAL REGISTRATION NUMBER: CRD42017060344.
引用
- Lees JS, Chapman FA, Witham MD, et al. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis. Heart. 2018. PMID: 30514729. doi:10.1136/heartjnl-2018-313955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。